Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

338
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
338
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.6K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

229
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
229
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

232
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
232

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Information Transfer Practices Between Hospitals and Primary Care for Older Adults: A Scoping Review.

Journal of the American Medical Directors Association·2026
Same author

Potato protein-based meat analogues fortified with upcycled fruit flours: Functional, textural, and antioxidant insights.

Food chemistry·2026
Same author

Longitudinal Analysis of HIV-2 Proviral DNA Reveals Archived Protease Inhibitor Resistance and Reservoir Evolution over Eight Years.

International journal of molecular sciences·2026
Same author

In vitro gastrointestinal digestion fate, bioaccessibility, and antioxidant activity of anthocyanins encapsulated in zein/polysaccharide composite nanocarriers.

Food chemistry·2026
Same author

Who packed the drugs? Improved DNA recovery and its impact on findings given activity-level propositions.

Forensic science international. Genetics·2026
Same author

Gut Microbiota Modulation by Carboxymethyl Cellulose and Carrageenan: Current Evidence and Health Implications.

Foods (Basel, Switzerland)·2026

Related Experiment Video

Updated: Feb 28, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Population Approach to Efavirenz Therapy.

Hélder Duarte1, João Paulo Cruz2, Natália Aniceto2

  • 1Departamento de Ciências Farmacológicas, Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal.

Journal of Pharmaceutical Sciences
|June 18, 2017
PubMed
Summary

Genetic variations in CYP2B6 significantly impact efavirenz (EFV) drug levels in HIV patients. Homozygous mutations necessitate EFV dose adjustments for effective treatment and to prevent toxicity.

Keywords:
CYP enzymesHIV/AIDSpharmacogeneticspopulation pharmacokineticstherapeutic drug monitoring

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.4K

Related Experiment Videos

Last Updated: Feb 28, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.4K

Area of Science:

  • Pharmacology
  • Genetics
  • Infectious Diseases

Background:

  • Efavirenz (EFV) is a crucial nonnucleoside reverse transcriptase inhibitor for HIV treatment.
  • High inter-individual variability in EFV plasma concentrations can lead to toxicity or treatment failure.
  • Understanding EFV pharmacokinetics is vital for optimizing patient outcomes.

Purpose of the Study:

  • To develop a population pharmacokinetic model for EFV.
  • To identify factors contributing to EFV concentration variability in HIV-positive individuals.
  • To predict EFV steady-state plasma concentrations more accurately.

Main Methods:

  • A population pharmacokinetic model was built using nonlinear mixed-effects modeling (Monolix®).
  • Data from 96 HIV-positive individuals were analyzed.
  • Covariates including demographics, biochemical parameters, HCV-HIV coinfection, and genetic polymorphisms were evaluated.

Main Results:

  • A one-compartment model with first-order kinetics described EFV data.
  • CYP2B6 gene polymorphisms (rs2279343 and rs3745274) were the sole significant covariates affecting EFV clearance.
  • Oral clearance varied significantly: 19.6 L/h (wild-type), 14.15 L/h (heterozygous), and 6.08 L/h (homozygous mutated).

Conclusions:

  • CYP2B6 genotype is a key determinant of EFV oral clearance.
  • Dose adjustment of EFV is recommended for individuals with homozygous CYP2B6 mutations.
  • Hepatitis C virus-HIV coinfection did not significantly influence EFV pharmacokinetics.